Ivonescimab vs JS207

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 + VEGFA · full Non-Small Cell Lung Cancer pipeline

Ivonescimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancerbispecific antibody
Reliable signal

NCT05499390 · Phase 3 · active, not recruiting

This trial randomized patients in a quadruple-blinded design comparing ivonescimab against an active comparator (pembrolizumab), with nearly 400 participants -- a reasonably powered sample for a Phase 3 oncology trial. The primary endpoint, progression-free survival by independent blinded review, is a hard clinical measure, and the result was statistically significant in favor of ivonescimab (11.1 vs 5.8 months, hazard ratio 0.51, p<0.0001), indicating a clear and well-supported benefit.

Next expected readout: December 2026 · NCT07086326 (registry estimate)

Reported efficacy

PFS assessed by IRRC per RECIST v1.1 (Up to 2 approximately years): HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized (met)

Result source: NCT05499390

JS207

Developed by Shanghai Junshi Bioscience

Phase 2 in Non-Small Cell Lung Cancerbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT06944470 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIvonescimabJS207
PFS, median—Trial running · NCT05840016—Not reported
OS, median—Trial running · NCT05840016—Not reported
ORR—Trial running · NCT05840016—Not reported
Duration of response, median—Trial running · NCT05840016—Not reported

PFS, median

Ivonescimab
—Trial running · NCT05840016
JS207
—Not reported

OS, median

Ivonescimab
—Trial running · NCT05840016
JS207
—Not reported

ORR

Ivonescimab
—Trial running · NCT05840016
JS207
—Not reported

Duration of response, median

Ivonescimab
—Trial running · NCT05840016
JS207
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JS207: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ivonescimab
HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized NCT05499390 · Phase 3 · design grade: strong · publication or press release
ORR 39.8% and DCR 86.1% in 108 patients; first-line PD-L1-positive ORR 33.3%, 52.6%, 60.0%, 75.0% by dose (10 mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W, 30 mg/kg Q3W); grade >=3 TRAEs 22.2% NCT04900363 · Phase 1/2 · design grade: weak · publication or press release
HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001 NCT05184712 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivonescimab's landscape · JS207's landscape